Lennox-Gastaut syndrome (LGS) is a severe and rare form of epilepsy, which causes patients to often have multiple seizures a day. It generally appears in early childhood, and is difficult to treat. In severe cases, it may be fatal. To learn more about LGS, click here.
Ovid Therapeutics Inc., a company that focuses on creating medicines for people with rare diseases, saw the need for a better LGS treatment. They have been working with Takeda Pharmaceutical Company Limited on the treatment TAK-935/OV935.
